JP2025518552A - 細胞を操作するための組成物及び方法 - Google Patents

細胞を操作するための組成物及び方法 Download PDF

Info

Publication number
JP2025518552A
JP2025518552A JP2024568584A JP2024568584A JP2025518552A JP 2025518552 A JP2025518552 A JP 2025518552A JP 2024568584 A JP2024568584 A JP 2024568584A JP 2024568584 A JP2024568584 A JP 2024568584A JP 2025518552 A JP2025518552 A JP 2025518552A
Authority
JP
Japan
Prior art keywords
cell
nucleic acid
certain embodiments
sequence
nuclease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024568584A
Other languages
English (en)
Japanese (ja)
Inventor
タニヤ・ウォーネック
ローランド・バウムガートナー
ジョン・シール
ニコラス・エイオン・ティミンズ
Original Assignee
セリントラ・セラピューティクス・エスア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セリントラ・セラピューティクス・エスア filed Critical セリントラ・セラピューティクス・エスア
Publication of JP2025518552A publication Critical patent/JP2025518552A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2024568584A 2022-05-16 2023-05-16 細胞を操作するための組成物及び方法 Pending JP2025518552A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263342472P 2022-05-16 2022-05-16
US63/342,472 2022-05-16
PCT/US2023/022439 WO2023225035A2 (fr) 2022-05-16 2023-05-16 Compositions et méthodes d'ingénierie de cellules

Publications (1)

Publication Number Publication Date
JP2025518552A true JP2025518552A (ja) 2025-06-17

Family

ID=88835951

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024568584A Pending JP2025518552A (ja) 2022-05-16 2023-05-16 細胞を操作するための組成物及び方法

Country Status (4)

Country Link
EP (1) EP4526333A2 (fr)
JP (1) JP2025518552A (fr)
CA (1) CA3253302A1 (fr)
WO (1) WO2023225035A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121039279A (zh) * 2023-05-05 2025-11-28 万达制药公司 反义寡核苷酸(aso)基因抑制和治疗
WO2025175136A1 (fr) * 2024-02-15 2025-08-21 The Board Of Trustees Of The Leland Stanford Junior University Anticorps anti-nkp46 et procédés d'utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7841846B2 (ja) * 2017-11-15 2026-04-07 ノヴォ ノルディスク アー／エス Ｆｘ活性化を促進する第ｘ因子結合剤
MX2023004505A (es) * 2020-10-19 2023-05-10 Caribou Biosciences Inc Polinucleotidos que contienen adn y guias para sistemas crispr de tipo v, y metodos de fabricacion y uso de los mismos.

Also Published As

Publication number Publication date
WO2023225035A3 (fr) 2024-02-08
EP4526333A2 (fr) 2025-03-26
WO2023225035A2 (fr) 2023-11-23
CA3253302A1 (fr) 2023-11-23

Similar Documents

Publication Publication Date Title
US12270044B2 (en) CRISPR systems with engineered dual guide nucleic acids
US20230083383A1 (en) Compositions and methods for targeting, editing or modifying human genes
US20250179481A1 (en) Compositions and methods for targeting, editing, or modifying genes
JP2025518552A (ja) 細胞を操作するための組成物及び方法
US20250034558A1 (en) Compositions and methods for targeting, editing or modifying human genes
US20260022404A1 (en) Compositions and methods for genome editing
US20250197811A1 (en) Compositions and methods for generating cells with reduced immunogenicity
US20250115903A1 (en) Compositions and methods for editing genomes
US20260071238A1 (en) Materials and processes for engineering hypoimmunogenicity
US20250388896A1 (en) Composition and methods for transgene insertion
JP2025535776A (ja) 遺伝子を標的化、編集又は修飾するための組成物及び方法
WO2024233505A9 (fr) Compositions et procédés de ciblage, d'édition ou de modification de gènes humains